JP2024513835A5 - - Google Patents
Info
- Publication number
- JP2024513835A5 JP2024513835A5 JP2023560404A JP2023560404A JP2024513835A5 JP 2024513835 A5 JP2024513835 A5 JP 2024513835A5 JP 2023560404 A JP2023560404 A JP 2023560404A JP 2023560404 A JP2023560404 A JP 2023560404A JP 2024513835 A5 JP2024513835 A5 JP 2024513835A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- antigen
- binding domain
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163170320P | 2021-04-02 | 2021-04-02 | |
| US63/170,320 | 2021-04-02 | ||
| US202263313927P | 2022-02-25 | 2022-02-25 | |
| US63/313,927 | 2022-02-25 | ||
| PCT/US2022/023122 WO2022212885A1 (en) | 2021-04-02 | 2022-04-01 | Stabilized formulations containing anti-muc16 x anti-cd3 bispecific antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024513835A JP2024513835A (ja) | 2024-03-27 |
| JP2024513835A5 true JP2024513835A5 (enExample) | 2025-04-08 |
Family
ID=81579790
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023560404A Pending JP2024513835A (ja) | 2021-04-02 | 2022-04-01 | 抗ｍｕｃ１６×抗ｃｄ３二重特異性抗体を含有する安定化製剤 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20220332849A1 (enExample) |
| EP (1) | EP4313008A1 (enExample) |
| JP (1) | JP2024513835A (enExample) |
| KR (1) | KR20230165828A (enExample) |
| AU (1) | AU2022246687A1 (enExample) |
| BR (1) | BR112023019096A2 (enExample) |
| CA (1) | CA3213546A1 (enExample) |
| CL (1) | CL2023002922A1 (enExample) |
| CO (1) | CO2023014918A2 (enExample) |
| IL (1) | IL306042A (enExample) |
| MX (1) | MX2023011469A (enExample) |
| TW (1) | TW202304507A (enExample) |
| WO (1) | WO2022212885A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102531251B1 (ko) * | 2016-09-23 | 2023-05-15 | 리제너론 파아마슈티컬스, 인크. | 이특이적 항-muc16-cd3 항체 및 항-muc16 약물 접합체 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0747045B2 (ja) | 1986-10-15 | 1995-05-24 | 株式会社大協精工 | 積層した注射器用滑栓 |
| JP3100727B2 (ja) | 1992-01-23 | 2000-10-23 | 株式会社大協精工 | 変性ポリシロキサン組成物及び該組成物を被覆した衛生ゴム製品 |
| JP3172057B2 (ja) | 1995-04-05 | 2001-06-04 | 株式会社大協精工 | ラミネートゴム栓 |
| JP3512349B2 (ja) | 1999-01-29 | 2004-03-29 | 株式会社大協精工 | 柱状ゴム要素の成形型 |
| JP2002209975A (ja) | 2001-01-19 | 2002-07-30 | Daikyo Seiko Ltd | 医薬バイアル用ラミネートゴム栓 |
| AU2003251592A1 (en) * | 2002-06-21 | 2004-01-06 | Biogen Idec Inc. | Buffered formulations for concentrating antibodies and methods of use thereof |
| MX366337B (es) * | 2010-10-06 | 2019-07-05 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleucina-4 (il-4r). |
| WO2016036678A1 (en) * | 2014-09-02 | 2016-03-10 | Medimmune, Llc | Formulations of bispecific antibodies |
| EP3411401A1 (en) * | 2016-02-03 | 2018-12-12 | Oncobiologics, Inc. | Buffer formulations for enhanced antibody stability |
| KR102531251B1 (ko) * | 2016-09-23 | 2023-05-15 | 리제너론 파아마슈티컬스, 인크. | 이특이적 항-muc16-cd3 항체 및 항-muc16 약물 접합체 |
-
2022
- 2022-03-31 TW TW111112453A patent/TW202304507A/zh unknown
- 2022-04-01 MX MX2023011469A patent/MX2023011469A/es unknown
- 2022-04-01 KR KR1020237037903A patent/KR20230165828A/ko active Pending
- 2022-04-01 BR BR112023019096A patent/BR112023019096A2/pt unknown
- 2022-04-01 JP JP2023560404A patent/JP2024513835A/ja active Pending
- 2022-04-01 US US17/711,800 patent/US20220332849A1/en active Pending
- 2022-04-01 WO PCT/US2022/023122 patent/WO2022212885A1/en not_active Ceased
- 2022-04-01 IL IL306042A patent/IL306042A/en unknown
- 2022-04-01 EP EP22720824.6A patent/EP4313008A1/en active Pending
- 2022-04-01 CA CA3213546A patent/CA3213546A1/en active Pending
- 2022-04-01 AU AU2022246687A patent/AU2022246687A1/en active Pending
-
2023
- 2023-09-29 CL CL2023002922A patent/CL2023002922A1/es unknown
- 2023-11-01 CO CONC2023/0014918A patent/CO2023014918A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102397713B1 (ko) | 안정한 액체 약제학적 제제 | |
| JP2024016177A5 (enExample) | ||
| FI4249512T3 (fi) | Stabiili vasta-aineformulaatio | |
| JP7278952B2 (ja) | 安定化された抗体タンパク質溶液 | |
| JP2020518600A5 (enExample) | ||
| WO2020094122A1 (zh) | 一种TGF-β受体融合蛋白药物组合物及其用途 | |
| JP2009507838A (ja) | 抗ｃｄ３抗体製剤 | |
| JP2020518598A5 (enExample) | ||
| JP2022532927A5 (enExample) | ||
| JP2016534052A5 (enExample) | ||
| JP2023071755A (ja) | 安定化された抗体溶液 | |
| JP2024544523A5 (enExample) | ||
| WO2010132872A1 (en) | Combination therapies and methods using anti-cd3 modulating agents and anti-tnf antagonists | |
| JP2025502061A5 (enExample) | ||
| JP2023507561A5 (enExample) | ||
| US20240409631A1 (en) | Aqueous formulations of an anti-cd22 antibody and uses thereof | |
| JP2023533963A5 (enExample) | ||
| JP2024513835A (ja) | 抗ｍｕｃ１６×抗ｃｄ３二重特異性抗体を含有する安定化製剤 | |
| US12364756B2 (en) | Pharmaceutical compositions of a PD-1 antibody and use of the same | |
| RU2024122332A (ru) | СПОСОБЫ ЛЕЧЕНИЯ РЕЦИДИВИРУЮЩЕГО РАКА ЯИЧНИКА С ПОМОЩЬЮ БИСПЕЦИФИЧНЫХ АНТИТЕЛ К MUC16 x CD3 ОТДЕЛЬНО ИЛИ В КОМБИНАЦИИ С АНТИТЕЛАМИ К PD-1 | |
| JP2021518393A5 (enExample) | ||
| JP2024535041A5 (enExample) | ||
| EA045933B1 (ru) | Водная фармацевтическая композиция левилимаба и ее применение | |
| HK40045548A (en) | TGF-β RECEPTOR FUSION PROTEIN PHARMACEUTICAL COMPOSITION AND USE THEREOF | |
| RU2018108050A (ru) | 5-бром-2,6-ди-(1н-пиразол-1-ил)пиримидин-4-амин для применения в лечении рака |